反应详情

Using an adaptation of the method described in Procedure 7, substituting N-[2-(10-piperidin-4-yl-10H-phenoxazin-3-yl)-phenyl]-acetamide, 2j for the TFA salt of 10-piperidin-4-yl-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 6a, sodium triacetoxyborohydride for tetramethylammonium borohydride, and a 3:1 mixture of 1,2-dichloroethane:THF for 100% 1,2-dichloroethane, the title compound N-(2-{10-[1-(1H-imidazol-2-ylmethyl)-piperidin-4-yl]-10H-phenoxazin-3-yl}-phenyl)-acetamide, 7j was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in H2O containing 0.1% TFA). MS m/z (MH+) 479.9.